<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02958579</url>
  </required_header>
  <id_info>
    <org_study_id>95-03-191-33053</org_study_id>
    <secondary_id>957275</secondary_id>
    <nct_id>NCT02958579</nct_id>
  </id_info>
  <brief_title>a Population Based Study on Metabolic Syndrome Complications, and Mortality</brief_title>
  <acronym>MetSCoM</acronym>
  <official_title>A Population Based Cohort Study on Metabolic Syndrome Complications, and Mortality; (MetSCoM) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tehran University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tehran University of Medical Sciences</source>
  <brief_summary>
    <textblock>
      Metabolic syndrome (MetS) is recognized as clustering of a number of components including
      hypertension, hypertriglyceridemia, low serum high-density lipoprotein cholesterol (HDL-C),
      impaired glucose metabolism (IGM), and abdominal obesity. It has been tightly linked to
      thrombotic vascular events including coronary heart disease (CHD). Worldwide prevalence of
      MetS is on the rise. People living in Iran, a country located in the Middle-East region, have
      distinct behavioral, environmental and social exposures which certainly affect the prevalence
      and incidence of metabolic syndrome and its comorbidities.We hypothesized that these factors
      may affect the course of metabolic syndrome and the burden that it imposes to the community.
      The purposes of MetSCoM are as follows;

        1. To find the incidence of T2D, microvascular complications of T2D (diabetic retinopathy,
           diabetic neuropathy and diabetic kidney disease), CVD, and mortality rate of subjects
           metabolic syndrome.

        2. To find the association of baseline, mean value during follow up visits and visit to
           visit variability in anthropometric variables and several metabolic laboratory variables
           with metabolic syndrome and its complications.

        3. To find the effect of behavioral variables and environmental exposures on the course of
           metabolic syndrome.

        4. To identify the best anthropometric, laboratory, life-style and environmental predictors
           of CVD and mortality rate in subjects with metabolic syndrome.

        5. To estimate the economic burden of metabolic syndrome and its related
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A biphasic observational study will be conducted on participants with any component of
      metabolic syndrome in Tehran, Iran. Phase one of the study is a cross-sectional study, while
      the second phase is a prospective cohort. In phase one of study, the prevalence of any
      metabolic disorder will be estimated in the study population and the association of
      biochemical variables, behavioral and environmental variables with each metabolic disorder
      will be investigated. Afterwards, through the phase two, those with any component of
      metabolic syndrome will be followed to record the incidence of diabetes, vascular
      complications of diabetes, non-alcoholic fatty liver disease, (NAFLD), cancers, mortality
      rate and finally estimation of economic burden of metabolic syndrome and its components in
      study population. Participants will be recruited from four health surveillance centers
      located at East, West, North and South of Tehran, the capital city of Iran. The latitude of
      Tehran is 35°41' North, and 51°25' East. Participants will be followed for at least 10 years
      and we plan to extend this time if possible. Anthropometric, biochemical, behavioral and
      meteorological measurements will done on scheduled timeline.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>incidence of CVD</measure>
    <time_frame>10 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>incidence of microvascular complications of T2D (diabetic retinopathy, diabetic neuropathy, diabetic kidney disease), and diabetic foot</measure>
    <time_frame>10 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>incidence of non-alcoholic fatty liver disease (NAFLD)</measure>
    <time_frame>10 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>incidence of colorectal, breast and cervical cancers</measure>
    <time_frame>10 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>mortality rate</measure>
    <time_frame>10 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>economic burden of metabolic syndrome</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">10000</enrollment>
  <condition>Metabolic Syndrome X</condition>
  <arm_group>
    <arm_group_label>Obesity</arm_group_label>
    <description>Body mass index (BMI) score &gt; 25.2 kg/m2 for women and &gt; 27.3 kg/m2 for men or Waist circumference &gt; 90 cm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pre-diabetics or diabetics</arm_group_label>
    <description>if any of followings is identified the participant is regarded as diabetics and will be recruited in this arm;
Fasting Plasma glucose (FPG) level ≥ 7.0 mmol/l (126 mg/dL)
Plasma glucose ≥ 11.1 mmol/l (200 mg/dL) two hours after a 75 g oral glucose load as in a glucose tolerance test
Symptoms of hyperglycemia and casual plasma glucose ≥ 11.1 mmol/l (200 mg/dL)
Glycated hemoglobin (A1C) ≥ 6.5% if any of followings is identified the participant is regarded as pre-diabetics and will be recruited in this arm;
1- FPG levels of 100-125 mg/dl (5.6-6.9 mmol/l). 2-Two-h plasma glucose (2HPP) in the 75 g oral glucose tolerance test of 140-199 mg/dl (7.8- 11.0 mmol/l)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hypertension</arm_group_label>
    <description>Systolic blood pressure (SBP) ≥ 130mmHgand/or diastolic blood pressure (DBP) ≥ 85mmHg or use of anti-hypertensive drugs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hypertriglyceridemia</arm_group_label>
    <description>Serum triglyceride ≥150 mg/dL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low high density lipoprotein -cholesterol (HDL-c)</arm_group_label>
    <description>Serum HDL-C of &lt;40 mg/dL for men, &lt;50 mg/dL for women,</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention will be done. Participants are on standard care and the treatments will be recorded because of observational nature of this study.</intervention_name>
    <arm_group_label>Obesity</arm_group_label>
    <arm_group_label>Pre-diabetics or diabetics</arm_group_label>
    <arm_group_label>Hypertension</arm_group_label>
    <arm_group_label>hypertriglyceridemia</arm_group_label>
    <arm_group_label>Low high density lipoprotein -cholesterol (HDL-c)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All community dwellers aged greater than 40 years who are willing to participate will be
        included if met any of the following eligibility criteria; (1) central obesity, or (2)
        obesity, or (3) T2D or prediabetes, or (4) hypertension, or (5) hypertriglyceridemia, or
        (6) low high density lipoprotein-cholesterol (HDL-C).
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Obesity or central obesity, or

          -  Diabetes (Fasting Plasma glucose (FPG) level ≥ 7.0 mmol/l (126 mg/dL), or Plasma
             glucose ≥ 11.1 mmol/l (200 mg/dL) two hours after a 75 g oral glucose load as in a
             glucose tolerance test, or Symptoms of hyperglycemia and casual plasma glucose ≥ 11.1
             mmol/l (200 mg/dL), or Glycated hemoglobin (A1C) ≥ 6.5%),

          -  pre-diabetes (FPG levels of 100-125 mg/dl (5.6-6.9 mmol/l), or 2-h plasma glucose
             (2HPP) in the 75 g oral glucose tolerance test of 140-199 mg/dl (7.8-11.0 mmol/l), or

          -  Hypertension (Systolic blood pressure (SBP) ≥ 130mmHgand/or diastolic blood pressure
             (DBP) ≥ 85mmHg or use of anti-hypertensive drugs), or

          -  Low HDL-c (Serum HDL-C of &lt;40 mg/dL for men, &lt;50 mg/dL for women,)

          -  Hypertriglyceridemia, (TG&gt;150 mg/dL)

        Exclusion Criteria:

          -  type 1 diabetes

          -  type 2 diabetes who required insulin therapy at baseline

          -  gestational diabetes

          -  Any malignancy, rheumatologic diseases, chronic kidney, lung or heart diseases at
             baseline at baseline

          -  known hepatitis due to infectious and auto-immune diseases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohsen Afarideh, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tehran University of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alireza Ghajar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tehran University of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alireza Esteghamati, MD</last_name>
    <email>esteghamati@tums.ac.ir</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zahra Aryan, MD, MPH</last_name>
    <email>aryanzahra@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tehran University of Medical Sciences</name>
      <address>
        <city>Tehran</city>
        <zip>13145-784</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alireza Esteghamati, M.D.</last_name>
      <email>esteghamati@tums.ac.ir</email>
    </contact>
    <contact_backup>
      <last_name>Zahra Aryan, MD, MPH</last_name>
      <email>aryanzahra@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Mohsen Afarideh, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alireza Ghajar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <results_reference>
    <citation>Heidari B, Nargesi AA, Hafezi-Nejad N, Sheikhbahaei S, Pajouhi A, Nakhjavani M, Esteghamati A. Assessment of serum 25-hydroxy vitamin D improves coronary heart disease risk stratification in patients with type 2 diabetes. Am Heart J. 2015 Sep;170(3):573-9.e5. doi: 10.1016/j.ahj.2015.06.017. Epub 2015 Jun 27.</citation>
    <PMID>26385042</PMID>
  </results_reference>
  <results_reference>
    <citation>Afarideh M, Aryan Z, Ghajar A, Noshad S, Nakhjavani M, Baber U, Mechanick JI, Esteghamati A. Complex association of serum alanine aminotransferase with the risk of future cardiovascular disease in type 2 diabetes. Atherosclerosis. 2016 Nov;254:42-51. doi: 10.1016/j.atherosclerosis.2016.09.009. Epub 2016 Sep 9.</citation>
    <PMID>27684605</PMID>
  </results_reference>
  <results_reference>
    <citation>Nargesi AA, Heidari B, Esteghamati S, Hafezi-Nejad N, Sheikhbahaei S, Pajouhi A, Nakhjavani M, Esteghamati A. Contribution of vitamin D deficiency to the risk of coronary heart disease in subjects with essential hypertension. Atherosclerosis. 2016 Jan;244:165-71. doi: 10.1016/j.atherosclerosis.2015.11.020. Epub 2015 Nov 23.</citation>
    <PMID>26647372</PMID>
  </results_reference>
  <results_reference>
    <citation>Aryan Z, Noshad S, Afarideh M, Esteghamati A. Comment on Sharif et al. HDL Cholesterol as a Residual Risk Factor for Vascular Events and All-Cause Mortality in Patients With Type 2 Diabetes. Diabetes Care 2016;39:1424-1430. Diabetes Care. 2016 Oct;39(10):e189. doi: 10.2337/dc16-1211.</citation>
    <PMID>27660132</PMID>
  </results_reference>
  <results_reference>
    <citation>Afarideh M, Noshad S, Ghajar A, Aryan Z, Khajeh E, Hosseini Shirvani S, Bonnet F, Esteghamati A. Family history of diabetes and the risk of coronary heart disease in people with or without type 2 diabetes. Diabetes Metab. 2017 Apr;43(2):180-183. doi: 10.1016/j.diabet.2016.07.032. Epub 2016 Sep 17.</citation>
    <PMID>27644597</PMID>
  </results_reference>
  <results_reference>
    <citation>Faghihi-Kashani S, Bonnet F, Hafezi-Nejad N, Heidari B, Aghajani Nargesi A, Sheikhbahaei S, Ebadi M, Esteghamati A. Fasting hyperinsulinaemia and 2-h glycaemia predict coronary heart disease in patients with type 2 diabetes. Diabetes Metab. 2016 Feb;42(1):55-61. doi: 10.1016/j.diabet.2015.10.001. Epub 2015 Oct 31.</citation>
    <PMID>26531321</PMID>
  </results_reference>
  <results_reference>
    <citation>Esteghamati A, Hafezi-Nejad N, Zandieh A, Sheikhbahaei S, Ebadi M, Nakhjavani M. Homocysteine and metabolic syndrome: from clustering to additional utility in prediction of coronary heart disease. J Cardiol. 2014 Oct;64(4):290-6. doi: 10.1016/j.jjcc.2014.02.001. Epub 2014 Mar 14.</citation>
    <PMID>24631466</PMID>
  </results_reference>
  <results_reference>
    <citation>Esteghamati A, Hafezi-Nejad N, Sheikhbahaei S, Heidari B, Zandieh A, Ebadi M, Nakhjavani M. Risk of coronary heart disease associated with metabolic syndrome and its individual components in Iranian subjects: a matched cohort study. J Clin Lipidol. 2014 May-Jun;8(3):279-86. doi: 10.1016/j.jacl.2014.02.002. Epub 2014 Feb 15.</citation>
    <PMID>24793349</PMID>
  </results_reference>
  <results_reference>
    <citation>Sheikhbahaei S, Fotouhi A, Hafezi-Nejad N, Nakhjavani M, Esteghamati A. Serum uric acid, the metabolic syndrome, and the risk of chronic kidney disease in patients with type 2 diabetes. Metab Syndr Relat Disord. 2014 Mar;12(2):102-9. doi: 10.1089/met.2013.0119. Epub 2014 Jan 21.</citation>
    <PMID>24447037</PMID>
  </results_reference>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 5, 2016</study_first_submitted>
  <study_first_submitted_qc>November 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 8, 2016</study_first_posted>
  <last_update_submitted>November 5, 2016</last_update_submitted>
  <last_update_submitted_qc>November 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

